{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:35:00Z","timestamp":1786469700868,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Greater insight into the effects of cystic fibrosis (CF) transmembrane modulators such as elexacaftor\u2010tezacaftor\u2010ivacaftor (ETI) on glucose metabolism can support a more dynamic and individualised approach to CF\u2010related dysglycaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess changes in glycemia, body weight and pulmonary function in adults with CF with and without cystic fibrosis related diabetes (CFRD) following ETI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single\u2010centre retrospective cohort study included adults with at least one F508del mutation (23 with CFRD, 38 without CFRD). Exploratory outcomes were HbA1c and total daily insulin doses in the CFRD group and glucose and insulin profiles (0\u2013120\u2009min oral glucose tolerance test [OGTT]), HOMA2\u2010derived indices of insulin resistance (IR), secretion (%S), and \u03b2\u2010cell function (%B) in the non\u2010CFRD group. Pulmonary function and weight were assessed in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean age was 33.8\u2009\u00b1\u200910.0\u2009years (CFRD) and 32.8\u2009\u00b1\u20098.8\u2009years (non\u2010CFRD), with median ETI exposure of 12.3 and 13.4\u2009months, respectively. In the CFRD cohort, HbA1c decreased non\u2010significantly (6.6% to 6.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.2) with no significant change in insulin dose (0.28 to 0.20\u2009IU\/kg\/day,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.1). In non\u2010CFRD participants, ETI significantly reduced 1\u2010 and 2\u2010hour OGTT glucose levels (9.6 vs. 9.2\u2009mmol\/L at 1\u2009h,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01; 6.1 vs. 4.8\u2009mmol\/L at 2 hours,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), with 13\/38 participants improving OGTT classification; no progression to CFRD occurred. Lung function improved in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adults with at least one F508del mutation, ETI was associated with a clinically relevant reduction in HbA1c in those with CFRD and improved glucose tolerance in those without, supporting favourable metabolic effects beyond established respiratory benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/imj.70471","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:15:43Z","timestamp":1782296143000},"page":"1356-1360","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triple combination\n                    <scp>cystic fibrosis transmembrane receptor<\/scp>\n                    modulator effects on glycaemia and insulin kinetics in cystic fibrosis with and without diabetes"],"prefix":"10.1111","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3835-4894","authenticated-orcid":false,"given":"Yi W.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Endocrinology Nepean Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Sleep Medicine Westmead Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Middleton","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Sleep Medicine Westmead Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-1370","authenticated-orcid":false,"given":"D. Jane","family":"Holmes\u2010Walker","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Westmead Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1768"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae857"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202411-2312OC"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf099"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.12.016"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2025.03.007"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.01.004"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.09.001"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2023.100320"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2022.100311"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101466"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.11.012"},{"key":"e_1_2_4_14_1","unstructured":"Diabetes Trials Unit (DTU) University of Oxford.HOMA2 Calculator (Version 2.2.4). Radcliffe Department of Medicine University of Oxford. Available at: ox.ac.uk (Updated 27 November 2019)."},{"key":"e_1_2_4_15_1","unstructured":"The jamovi project(2025).jamovi (Version 2.6) [Computer Software]. Retrieved fromhttps:\/\/www.jamovi.org. Sydney Australia."},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.11.005"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-070328"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ncp.10454"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0690"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2025.112984"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.70471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:42:47Z","timestamp":1786466567000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.70471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/imj.70471"],"URL":"https:\/\/doi.org\/10.1111\/imj.70471","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"2026-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}